Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 282
- Registration Number
- NCT02191579
- Locations
- 🇺🇸
Kansas City Bone and Joint Clinic, Overland Park, Kansas, United States
🇺🇸Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States
🇺🇸California Headache and Balance Center, Fresno, California, United States
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Allergan
- Target Recruit Count
- 200
- Registration Number
- NCT02188173
- Locations
- 🇺🇸
Raj Maturi, MD PC, Indianapolis, Indiana, United States
🇺🇸Texas Retina Associates, Arlington, Arlington, Texas, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 151
- Registration Number
- NCT02186119
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT02181504
- Locations
- 🇯🇵
Nihon University Hospital, Chiyoda-ku,Tokyo, Japan
🇯🇵1 Fukushima Medical University, Fukushima-shi, Japan
🇯🇵Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka, Japan
Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 43
- Registration Number
- NCT02181530
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT02181517
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 116
- Registration Number
- NCT02176356
A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 80
- Registration Number
- NCT02176421
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 515
- Registration Number
- NCT02161159
- Locations
- 🇩🇪
Andreas Reinhard Wicht, Sangerhausen, Germany
🇩🇪Franz Hirschle, Singen, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 240
- Registration Number
- NCT02161146
© Copyright 2024. All Rights Reserved by MedPath